Clinical trials: Respiratory Synctial Virus, open to volunteers
COVID -19, Influenza A
Clinical Validation of the Aptitude Medical Systems Metrix Respiratory Panel Test in At-Home/Non-Laboratory Settings
The Metrix Respiratory Panel Test will be evaluated for use in Non-Laboratory settings in a home testing environment utilizing the clinical study design described herein.
- Conditions
- COVID -19, Influenza A, Influenza B, Respiratory Synctial Virus
- Trial name
- NCT07217639
- Testing
- Aptitude Medical Systems Respiratory Panel Test
- Where
- United States
- Volunteers
- 2,000 people
- Sponsor
- Aptitude Medical Systems
Respiratory Synctial Virus Infections
Evaluation of the Effect of Nirsevimab on Hospitalizations Due to RSV Infection in Infants Under One Year of Age.
This study aims to evaluate the impact of Nirsevimab, a monoclonal antibody used for RSV prophylaxis, on reducing RSV- related hospitalizations. It will be conducted at 8 pediatric departments in Tuscany, Italy.
- Trial name
- NCT06856967
- Testing
- Nirsevimab
- Where
- 8 sites in Italy
- Volunteers
- 138 people
- Sponsor
- Meyer Children's Hospital IRCCS
Respiratory Synctial Virus, Asthma Childhood
Infant RSV Immunity Study
Respiratory Syncytial Virus (RSV) is a main global cause of respiratory illness and death in infants. Previous infant vaccine trials have failed to demonstrate protection.
- Trial name
- IRIS (NCT07653347)
- Where
- Canada
- Volunteers
- 300 people, healthy volunteers welcome
- Sponsor
- University of British Columbia